EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma

International Journal of Molecular Sciences

Vanessa Szablewski⁴  Jérôme Solassol⁴  Flora Poizat⁴  Marion Larrieux⁴  Louis Crampette¹  Alain Mange³  Caroline Bascoul-Mollevi² 

[1] Department of Surgery, Centre Hospitalier Universitaire de Montpellier, Montpellier 34000, France; E-Mail:;Department of Biostatistic, CRLC Val d’Aurelle, Montpellier 34000, France; E-Mail:;Faculté de Médecine de Montpellier, Université de Montpellier I, Montpellier 34000, France; E-Mail:;Department of Biopathology, Centre Hospitalier Universitaire de Montpellier, Montpellier 34000, France; E-Mails:

关键词: ITAC;    KRAS;    BRAF;    EGFR expression;    prognosis marker;   

DOI  :  10.3390/ijms14035170

来源: mdpi

【 摘 要 】

Accumulation of molecular alterations, including EGFR overexpression and mutations in KRAS and BRAF, contribute to colorectal carcinogenesis. Since intestinal-type adenocarcinoma (ITAC) of the nasal cavity and paranasal sinus has morphologic and phenotypic features that are usually indistinguishable from colorectal cancer (CRC), it is likely that both tumor types share equivalent genetic alterations. Data from a series of 43 patients treated surgically for ITAC in Montpellier, France between November 1998 and December 2012 were collected. Tumors were characterized for mutations in KRAS and BRAF as well as EGFR overexpression. Kaplan-Meier survival curves were constructed using overall survival as the primary end points. Patient survival was analyzed using the hazards ratio. Twenty seven tumors (63%) showed EGFR positivity and 30% exhibited a high expression level (+2/+3). KRAS mutations were detected in 43% of cases. BRAF mutations were identified in 3.6% of specimens. Patients with age superior to 60 years, metastatic status, and KRAS mutations had significant overall survival values (p = 0.026, p = 0.001 and p = 0.03, respectively). Our results indicate that KRAS mutations and EGFR expression are frequent in ITAC and that KRAS mutations predict good patient prognosis in ITAC. Finally, EGFR directed molecular treatments could be investigated in a subset of patients affected by ITAC.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.